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s u m m a r y 
Genomic surveillance of bacterial meningitis pathogens is essential for effective disease control globally, 
enabling identification of emerging and expanding strains and consequent public health interventions. 
While there has been a rise in the use of whole genome sequencing, this has been driven predominately 
by a subset of countries with adequate capacity and resources. Global capacity to participate in surveil- 
lance needs to be expanded, particularly in low and middle-income countries with high disease burdens. 
In light of this, the WHO-led collaboration, Defeating Meningitis by 2030 Global Roadmap, has called 
for the establishment of a Global Meningitis Genome Partnership that links resources for: N. meningitidis 
(Nm), S. pneumoniae (Sp), H. influenzae (Hi) and S. agalactiae (Sa) to improve worldwide co-ordination of 
strain identification and tracking. Existing platforms containing relevant genomes include: PubMLST: Nm 
(31,622), Sp (15,132), Hi (1935), Sa (9026); The Wellcome Sanger Institute: Nm (13,711), Sp ( > 24,0 0 0), 
Sa (6200), Hi (1738); and BMGAP: Nm (8785), Hi (2030). A steering group is being established to coor- 
dinate the initiative and encourage high-quality data curation. Next steps include: developing guidelines 
on open-access sharing of genomic data; defining a core set of metadata; and facilitating development of 
user-friendly interfaces that represent publicly available data. 
© 2020 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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Meningitis, and related invasive bacterial infections such as bac-
eraemic pneumonia and sepsis, are devastating diseases that rep-
esent a major global health challenge. 1 , 2 While successful immu-
isation programmes against three of the main bacterial causes,
eisseria meningitidis (Nm, the meningococcus), Streptococcus pneu-
oniae (Sp, the pneumococcus), and Haemophilus influenzae
ype b (Hib), have enabled great progress to be made, the bur-
en remains high with progress substantially behind that of other
nfectious diseases. According to one estimate, between 1990 and
017 child (under five) meningitis deaths fell by just 53%, com-
ared to 70% for diarrhoea, 87% for measles, and 93% for tetanus. 3 
In the African meningitis belt, large epidemics of meningococ-
al disease occur periodically. Although there have been dramatic
eclines in Nm serogroup A (NmA) disease following successful
enAfriVac® mass vaccination campaigns, the threat of both en-
emic and epidemic disease caused by non-A Nm and Sp persists 4 ,
ith Africa as a whole still experiencing the greatest global burden
f bacterial meningitis. Epidemiological data underlying global bur-
en estimates, particularly in Asia, remain incomplete, however. 5 
ucleotide sequence-based typing, in particular whole genome se-
uencing (WGS), has important applications for tracking and re-
ponding to endemic and epidemic disease. 
GS to elucidate the origin and spread of new strains for 
ublic health management 
Outbreaks of Nm serogroup C (NmC) disease were rare in the
eningitis belt until 2013, when North-Western Nigeria experi-
nced localised outbreaks caused by a novel NmC strain (the ST-
0217 clonal complex; cc10217). 6 In 2015, this strain caused a
evere epidemic in Niger 7 and, in 2017, the largest ever known
utbreak of NmC disease in Nigeria, with over 14,0 0 0 suspected
ases. 8 , 9 The analysis and comparison of WGS data successfully
lucidated the origin and spread of this new strain that emerged
fter the acquisition of virulence genes by a non-encapsulated,
on-virulent ancestor. 10 Metagenomic approaches have since re-
ealed that NmC cc10217 has spread outside the meningitis belt,
ausing an outbreak associated with a funeral in Liberia in 2017. 11 
Genomic approaches were also able to resolve Nm serogroup W
NmW) ST-11 clonal complex (cc11) isolates into multiple strains
ithin two divergent sublineages: (i) the ‘Hajj-strain sublineage’,
named after a constituent strain that caused a global outbreak
mong Hajj pilgrims in the early 20 0 0s); and, (ii) the ‘South
merican-strain sublineage’ that recently spread from South Amer-
ca to Europe and beyond. 12 Identification of the emergence and
xpansion of the South American-strain sublineage in the United
ingdom (U.K.) led to introduction of MenACWY conjugate vacci-
ation for adolescents. A novel, seemingly more virulent, variant,
he ‘2013-strain’ has since expanded into Europe, Australasia and
orth America 13 with consequential vaccine policy changes in Ire-
and, the Netherlands, Switzerland and Australia. 
WGS also has important applications in the development of
accines to control endemic disease. Indeed the identification of
he recombinant antigens used in Bexsero®, a protein- based vac-
ine that targets Nm serogroup B (NmB) disease, marked the first
se of genomics for vaccine antigen discovery through a ‘reverse
accinology’ approach. 14 Prior to this, broadly protective MenB vac-
ine development was hindered by the fact that NmB polysaccha-
ide is poorly immunogenic and has possible autoimmune effects,
ue to its similarities with human glycoproteins 15 , while candidate∗ Corresponding author. 
E-mail address: elizabethr@meningitis.org (E. Rodgers). 
b  
b  
o  
guter-membrane vesicle vaccines offered limited protection. Two
ecombinant protein MenB vaccines, Trumenba® and Bexsero® are 
urrently licensed for use in multiple countries worldwide, with
he latter routinely used in the U.K., Ireland, Lithuania, Andorra,
an Marino and South Australia 16 , while regions of Italy routinely
se both Trumenba® and Bexsero®. While these vaccines are ex-
ected to provide broad coverage of circulating NmB strains 17 , 18 ,
n-going global genomic surveillance is required to provide evi-
ence of vaccine impact, document strain coverage, monitor vac-
ine escape and to facilitate development of next generation vac-
ines. 19 , 20 
WGS has an important role to play in the surveillance of inva-
ive pneumococcal disease (IPD), which includes meningitis, bac-
eraemic pneumonia, and sepsis and remains a leading global
ause of mortality, especially among children. 21 –23 Under immune
elective pressure 24 the pneumococcus can escape pneumococcal 
onjugate vaccine (PCV) control through serotype replacement. The
ncrease of non-vaccine serotypes, concomitant with a decrease
n vaccine serotypes, 25 highlights the importance of monitoring
erotypes circulating pre- and post-PCV introduction to enable in-
asive non-vaccine pneumococcal serotypes to be rapidly identi-
ed. 17 WGS has enabled far greater insight into this process. 
Genomics has been used to investigate serotype replacement af-
er the introduction of both the original (PCV7) and higher valency
PCV10 and PCV13) vaccines, and emerging non-vaccine serotypes
ave been found to vary extensively among countries. Using
enome-wide variation, an international definition of pneumo-
occal population structure ‘Global Pneumococcal Sequence Clus-
ers (GPSCs)’ has been developed and enables the production of
neumococcal datasets, independent of previous definitions of lin-
ages. 26 Using this cluster definition, it was revealed that, post-
CV13 introduction, the top emerging cluster, GPSC3, expressed
erotype 8 in South Africa, but 33F in Israel and the United States
U.S.). 27 This demonstrates how species-wide approaches can en-
ble the evolution of the pneumococcus to be better tracked, be-
ond the limits of serotype. 
At the time of writing, comprehensive genome studies investi-
ating the meningococcus and the pneumococcus were available,
ut such studies for H. influenzae were more limited. It is impor-
ant to ensure that this pathogen is adequately examined, as, de-
pite dramatic reductions in Hib disease following global vaccine
mplementation, with 192 countries having introduced a univer-
al Hib vaccination programme by 2019 28 , H. influenzae meningitis
aused by other types still occurs. 29 For example, increasing rates
f invasive disease due to H. influenzae type a (Hia) have been de-
cribed in indigenous populations in northern Canada, Alaska, the
outhwestern U.S. and Australia, with an additional study indicat-
ng that H. influenzae strains are able to capsule-switch or mod-
late the expression of the type b capsule. 30 –32 Unencapsulated
on-typeable H. influenzae strains (NTHi) are also increasingly as-
ociated with invasive disease, including bacteraemic pneumonia.
hese organisms represent a growing challenge in healthcare set-
ings, particularly as many are antibiotic resistant. 33 
As of mid-2020 Streptococcus agalactiae (GBS), a leading cause
f neonatal meningitis and sepsis, was not yet vaccine-preventable,
lthough vaccines were in development. 34 –36 An increasing num-
er of WGS studies investigating GBS were becoming available,
ncluding some from low income countries, indicating a growing
wareness of this infection alongside the benefits of WGS data in
nderstanding the epidemiology of this pathogen. 37 
Consequently, continued surveillance and characterisation of 
acteria associated with meningitis remain a priority, if the global
urden of meningitis is to be reduced. The availability of sequence-
ased data will play an essential role in strengthening surveillance
f disease types and enabling interventions to be appropriately tar-
eted. 
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genome partnership 
The need for a Global Meningitis Genome Library (GMGL) was
identified in May 2017 at a meeting of international experts hosted
by Wilton Park, 38 and led by Meningitis Research Foundation
(MRF) in collaboration with the World Health Organization (WHO).
This meeting first outlined a global vision to defeat meningitis
and called for an action plan in line with the United Nations Sus-
tainable Development Goals (SDGs). 39 , 40 Subsequent consultations
led to the establishment of a Global Meningitis Genome Partner-
ship (GMGP) to link resources for the four leading causes of acute
bacterial meningitis, with the aim of improving worldwide co-
ordination of strain identification and tracking, and enabling the
public health benefits of WGS to be delivered. 
A Technical Task Force 41 co-ordinated by WHO developed a
Global Roadmap to Defeat Meningitis by 2030, which will be sub-
mitted for consideration at the World Health Assembly in 2020.
The roadmap focuses on the main causes of acute bacterial menin-
gitis that are already vaccine-preventable or may be in the fore-
seeable future: N. meningitidis, S. pneumoniae, H. influenzae, and S.
agalactiae . Sequence-based data are one key element to the global
vision to defeat meningitis, and therefore the importance of the
establishment of a GMGP functional for the four pathogens has
been highlighted by the Task Force. The terminology ‘partnership’
(within which libraries, or data repositories and platforms play a
crucial part), reflects the collaborative approach required for the
work that needs to be done. 
This article provides an account of the current status of menin-
gitis genomics globally and, in particular, focuses on: (i) review-
ing existing platforms that facilitate the submission and analysis
of WGS data; (ii) describing the efforts of existing global projects
and partners focused on enhancing surveillance and increasing our
understanding of these bacteria, particularly in resource-poor set-
tings; and, (iii) discussing the complexities associated with en-
suring globally representative datasets can be obtained and made
publicly available. 
Examples of existing meningitis pathogen genome libraries and
analysis platforms 
PubMLST 
The open-access PubMLST.org website and its underlying web-
based software platform, the Bacterial Isolate Genome Sequence
Database (BIGSdb), include all levels of sequence data enabling
a hierarchical approach to studying microbial species from single
gene fragments, to functional genes grouped into schemes, up to
full genome comparisons. 42 The integration of isolate characterisa-
tion, linking genotypes and genetic variation with provenance and
phenotype data, addresses a wide range of functional questions,
from population biology to antimicrobial resistance (AMR) and vac-
cine formulation, all of which can inform public health policies. 
At the time of writing the PubMLST databases hosted over
100 species and/or genera, including curated databases for the
four meningitis pathogens. This included > 30,0 0 0 N. meningitidis
genomes , > 15,0 0 0 S. pneumoniae genomes, > 90 0 0 S. agalactiae
genomes and 1900 H. influenzae genomes, predominantly submit-
ted from high-income regions or international centres. 
PubMLST is based on gene-by-gene population consensus anno-
tation, where genes are identified and their variation catalogued
systematically. 43 As a result, the genetic variation of every gene
in every bacterial genome can, in principle, be linked with prove-
nance and phenotypic information. 44 Users can perform a suite of
analyses, including: evolutionary analyses, bacterial species classi-
fication, disease surveillance, phylogeography and outbreak anal-ses. The provision of a common nomenclature, i.e. a universal
anguage to describe bacterial strains and lineages, is integral to
ts success, enabling portable use of this infrastructure and allow-
ng global laboratories and public health agencies to compare iso-
ates of interest, including foodborne pathogens. As a result, enteric
athogen outbreaks have been detected and halted through quick
ecognition of the same strain from different sources. 45 –47 
In addition to providing curated genomes, visual analytic tools
nable users to assess WGS genetic relatedness with integrated,
hird-party software, such as: (i) GrapeTree 48 and/or PhyloViz 49 ;
ii) Interactive Tree of Life (iTOL) 50 ; and (iii) MicroReact, which re-
pectively enable the creation of minimum spanning trees, phylo-
enetic trees and the visualisation of genomic epidemiology and
hylogeography ( Fig. 1 ). 51 
The PubMLST.org Neisseria site is one of the largest single
atabases within PubMLST ( Fig. 2 ). 52 Data are actively curated with
enomes submitted by users internationally. Additionally, curators
ometimes assemble genomes from short read data from the Eu-
opean Nucleotide Archive (ENA) and associate these with pub-
ished metadata. Curated data are made freely available and acces-
ible via the website or application programming interfaces (APIs).
his enables third party analysis sites to interconnect with the
atabase, facilitating open sharing of publicly available genomic
ata. Through APIs, comparisons can be made between private
ata, containing clinically sensitive information, and publicly avail-
ble data, enabling individual databases to act synergistically. 53 
The PubMLST Neisseria database contains several datasets, in-
luding comprehensive meningococcal genome libraries for Eng-
and and Wales (July 2010-present), 54 Scotland (2009-present) and
reland (2010–2014); however, it is not yet globally representa-
ive. As of March 2020, 127 countries had submitted meningococ-
al isolates with sequence data but only 97 countries had submit-
ed meningococcal genomes and the number of genomes submit-
ed ( n = 31,622) was approximately half of the number of isolates
 n = 60,776); the proactive collection and curation of comprehen-
ive and representative country-specific genome data from around
he world could remedy this. 
The PubMLST.org S. pneumoniae database contains over 15,0 0 0
enomes of which over 90 0 0 were included in the first version
f the Pneumococcal Genome Library. The library aims to pro-
ide users with assembled pneumococcal genome data and corre-
ponding metadata, as well as an assessment of genome quality
mong published data. It was developed following a review of ar-
icles with at least one pneumococcal genome; 979 articles were
creened on PubMed, and 173 peer-reviewed publications iden-
ified, of which 97 (56%) provided retrievable pneumococcal ge-
omic data without discrepancies ( e.g. missing or incorrect genome
equence accession numbers). Upon first release, the library con-
ained data from 92 publications, from 41 countries collected be-
ween 1916 and 2018, representing > 90 serotypes. Effort s are un-
erway to resolve discrepancies in the remaining 76 publications
nd enable upload of the associated genomes. 
BIGSdb is also used by the Institut Pasteur, Paris to run their 18
atabases of MLST and genome-based typing schemes. The plat-
orm provides reference nomenclatures for microbial isolates, pri-
arily intended for molecular epidemiology of pathogens of public
ealth importance, detection of virulence and AMR genes, and for
opulation biology research. 
he Wellcome Sanger Institute 
The Wellcome Sanger Institute has active research for a number
f meningitis-causing pathogens. 55 Datasets represent broad geo-
raphic and temporal ranges that are of value for evolutionary and
pidemiological analyses, but also include densely sampled collec-
ions that elucidate patterns of pathogen transmission and spread.
Establishing a global meningitis genome partnership / Journal of Infection 81 (2020) 510–520 513 
Fig. 1. Phylogeographic, temporal, and phylogenic visualisation tool Microreact available through the PubMLST.org website. Collection of 107 characterised meningococcal 
isolates chosen to be representative of disease globally in the latter half of the 20th century. 
Fig. 2. PubMLST Neisseria database: isolate and genome submissions over time. 
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i  Databases of all publicly available genomes are compiled and in-
frastructure is being developed to enable public access to data and
analysis tools. 
A data collection for Neisseria genome analyses has been estab-
lished that gathers all publicly available Neisseria WGS data from
the ENA and all available associated metadata, accessed from the
PubMLST.org Neisseria database and the published literature. This
has generated a collection of genomes from 32,538 isolates, from
77 countries, collected between 1937 and 2014. Of these, 16,164 are
Nm isolates, with metadata available for 13,711. However, a signifi-
cant proportion of the Nm isolates are from the U.K. ( n = 4256) and
other resource-rich countries; therefore some effort is still neces-
sary to establish truly global collections of Neisseria isolates. 
The Sanger pneumococcal database includes the Global Pneu-
mococcal Sequencing (GPS) project, which aims to assess the risk
of pneumococcal vaccine evasion by sampling population genomic
evolution before and after vaccine implementation, to inform fu-
ture vaccine and surveillance strategies. 56 , 57 The GPS project has
generated over 24,0 0 0 high-quality genomes (3105 from meningitis
cases) from 58 countries, with an emphasis on low- and middle-
income countries (LMICs) where disease burden is highest. Exten-
sive metadata for 13,454 of the genomes and interactive visualisa-
tions are available via Pneumogen.net 58 and Pathogenwatch. 59 
A global genomic survey of GBS (‘JUNO’) is now underway, aim-
ing to provide data and insights to inform vaccine strategies and
elucidate the routes of infection leading to infant mortality. Like
the GPS project, it will focus on training partners from LMICs to
increase access to genome data analysis, and 26 founding partner
institutions from 12 countries (mostly African countries) have al-
ready agreed to participate in this initiative. 
The Bacterial Meningitis Genome Analysis Platform 
In addition to global genome collections, platforms customised
for country specific needs have been developed, including the U.S.
Centers for Disease Control and Prevention (CDC) Bacterial Menin-
gitis Genome Analysis Platform (BMGAP). BMGAP is an automated
genomic analysis platform focused on H. influenzae and N. menin-
gitidis that streamlines workflows and reduces analysis time. 
BMGAP relies on PubMLST nomenclature and many functions
overlap with PubMLST; however, clinical data access is tightly re-
stricted, requiring state permission, and access to BMGAP requires
user registration. Due to the low burden of disease in the US, even
anonymised data may be traceable to an individual if precise de-
tails of time, place, and clinical data are published with genomes;
therefore, clinical data sharing is closely regulated, often requiring
additional approval. However, U.S. sequencing data from BMGAP
can be made publicly available in PubMLST, in compliance with
CDC data-sharing policies, with strictly limited access to sensitive
metadata and epidemiological data, to enable the systems to cross-
talk. 
Enhancing country representation and access through global 
partner support 
Current bacterial meningitis genome repositories are over-
representative of the locations where users already have capacity
and access to sample collections and understand the benefits of
WGS, or where users are collaborating with those who can obtain,
culture and sequence patient samples. As a result, sequences from
countries important in the emergence and spread of strains, but
who lack capacity, resources, and/or funding, or who are not au-
thorised to share data with new partners or collaborators, may be
absent from current collections. 
To develop globally representative genome repositories, a proac-
tive approach which utilises partner engagement is needed. WHOs committed to helping promote the benefits of WGS through re-
ional and country links, and through existing networks such as
he Invasive Bacterial Vaccine-Preventable Diseases (IB-VPD) global
urveillance network. 60 
The Global Meningococcal Initiative (GMI) 61 also has an impor-
ant role to play in promoting the benefits of WGS and participa-
ion in a GMGP among its collaborators. The GMI is a multidisci-
linary expert group, with members across 37 countries. It aims
o prevent invasive meningococcal disease worldwide through ed-
cation, research, and international collaboration. The role of the
MI is particularly important in regions such as Eastern Europe,
sia and the Pacific where formal meningitis surveillance is less
stablished. 62 A GMI meeting in China fostered a China-U.K. col-
aboration for the characterisation of a collection of Chinese NmW
solates 63 that were shown to be distinct from the Hajj- and South
merican-strain sublineages previously described. 64 The collabora-
ion further documented the disappearance of NmA and the emer-
ence of new NmB clones. The GMI is currently engaging with
astern European countries to investigate the persistence of NmA
isease in Kazakhstan. 65 
A further approach to engaging with countries not currently
ubmitting to WGS repositories is through funding time-limited
rojects that establish partnerships between countries that have
apacity and expertise in DNA extraction and sequencing, with
hose that do not. Data ownership and control over the level of
etadata shared would reside with the corresponding country,
wing to the codes of practice to be established regarding use of
epositories and publication of data. Projects such as the Menin-
itis Research Foundation-Meningococcal Genome Library (MRF-
GL), which includes comprehensive meningococcal genome li-
raries for England, Wales and Scotland, have been very suc-
essful in establishing representative epidemiological collections
f isolates, which have continued to be maintained and updated
 Fig. 3 a, b). 66 
neumococcal African Genomes (PAGe) consortium 
A project-based approach can also successfully deliver training
nd capacity building. The Pneumococcal African Genomes project
PAGe) is a consortium led by the Malawi-Liverpool-Wellcome
rust, with primary partners in Niger, South Africa, The Gambia,
nd the U.K. PAGe focused on genomic analyses of the pneumo-
occus across Africa, collecting over 800 isolates, sequenced at
he Wellcome Sanger Institute and establishing collaborations with
8 countries. In addition to encouraging dialogue between African
ites, this project trained bioinformaticians in centres in The Gam-
ia, Malawi and South Africa. This enabled the analysis of data at
 local level, and revealed that serotype 1 in West Africa is distinct
rom serotype 1 across the rest of the continent. 67 –71 Furthering
pidemiological understanding of this serotype, one of the major
auses of life threatening IPD in sub-Saharan Africa, marks an im-
ortant contribution towards vaccine target discovery and develop-
ent. 
olecular Epidemiology for Vaccination Policy 
Molecular Epidemiology for Vaccination Policy (MEVacP) is an-
ther example of a project-based approach that aims to improve
lobal public health by enhancing the diagnosis and surveillance
f bacterial meningitis caused by meningococcus, pneumococcus,
. influenzae and GBS, through building networks in low-income
ountries, with an initial emphasis on Africa. The aim of this
roject, funded by National Institute for Health Research (NIHR)
nd led by the University of Oxford, is to improve the characterisa-
ion and visualisation of outbreaks across the meningitis belt and
nform public health vaccination policies, through development
Establishing a global meningitis genome partnership / Journal of Infection 81 (2020) 510–520 515 
Fig. 3. Meningococcal genomes submitted to the PubMLST Neisseria database, as part of the U.K. Meningococcal Genome Library characterised by core genome MLST 
(cgMLST), 1605 loci, from 2009 to late 2019 ( n = 4242); (a) coloured by year; (b) coloured by clonal complex. 
516 Establishing a global meningitis genome partnership / Journal of Infection 81 (2020) 510–520 
Table 1 
Meningococcal meningitis in 10 African countries, 2018 [Source: WHO weekly bulletin] 76 . 
Countries # Meningitis suspected cases # CSF performed # Pos # Nm pos %CSF performed % Nm pos % pos 
Benin 322 320 7 1 99% 0.3% 2% 
Burkina Faso 2421 1590 211 41 66% 3% 13% 
Cameroon 1060 111 5 2 10% 2% 5% 
CAR 467 699 37 3 150% 0% 5% 
Chad 401 304 102 34 76% 11% 34% 
Ghana 987 910 89 39 92% 4% 10% 
Mali 755 707 126 13 94% 2% 18% 
Niger 1496 1151 543 447 77% 39% 47% 
Nigeria 4516 804 310 257 18% 32% 39% 
Togo 683 1679 38 3 246% 0.2% 2% 
All countries (25) 20,843 8650 1531 850 42% 10% 18% 
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qand implementation of a PubMLST-associated web-based platform
‘African Meningitis Epidemiology in Real Time’ (AMERT). AMERT
will operate a peer-to-peer private website similar to the Euro-
pean counterpart, EMERT 72 , whereby data in the system are only
available to submitters. With restricted access, reference laborato-
ries are reassured that data will remain private, which encourages
submissions to be made. Once published in journals, the data can
be made publicly available. 
Strengthening country laboratory capacity 
Currently, molecular surveillance in LMICs is largely driven by
expert international centres based in richer countries. In general,
LMICs frequently lack laboratory capacity, and have limited ac-
cess to bioinformatic tools and support, thus limiting opportuni-
ties for using sequence-based approaches and the interpretation of
sequencing data to identify the causative agents of disease. 60 Exist-
ing capacity needs to develop from a reliance on external support,
towards surveillance that is directed and delivered by the region
in the short term and by individual countries in the long term.
To facilitate this, national and regional laboratories with capacity
to perform molecular surveillance need to first be identified, and
connected, before progress can be made at a country level. How-
ever, to decentralise capacity to the country level, greater resource
and technical support is required at all levels to achieve sustain-
able molecular surveillance based on WGS. The rapid development
of the technology and the supporting software may assist in this
process. 
The WHO Collaborating Centers (CCs), the Norwegian Institute
for Public Health, the U.S. CDC, the Institut Pasteur Paris, the Med-
ical Research Council Unit The Gambia at the London School of
Hygiene and Tropical Medicine (MRCG at LSHTM), and the Global
Reference Laboratory for the IB VPD Surveillance Network at the
U.S. CDC have laid the foundation for global meningitis genome
surveillance by strengthening country capacity for surveillance,
laboratory diagnostics and outbreak investigation, particularly in
Africa. However, the recovery of isolates from epidemic areas of
the African meningitis belt remains low. 73 , 74 Data from the WHO
weekly bulletins show a low but rising proportion of reported
cases with cerebrospinal fluid (CSF) samples obtained and anal-
ysed, from ∼10% to nearly 40% over the past 13 years. While there
has been some improvement, still in very few of the analysed CSF
samples is the pathogen identified and isolate preserved ( Fig. 4 ). 75 
In 2018, 7.4% of the cases had an identified aetiology compared to
2.4% in 2007. Substantial variation among countries is also seen
regarding the proportion of cases that have lumbar punctures per-
formed and pathogens isolated ( Table 1 ). 76 
The transfer of clinical specimens to national and international
laboratories where sequencing can be performed is also challeng-
ing. Typically, the WHO CCs receive isolates from < 10% of re-orted cases ( Table 2 ). 75 Due to the challenges in performing cul-
ure, many laboratories are introducing real-time, or quantitative,
CR (qPCR), bypassing the need for culture, which at present is a
rerequisite for routine WGS. WGS requires viable isolates to be
btained which can be problematic, particularly if the patient has
eceived antimicrobial therapy. 
MenAfriNet, 77 an international consortium that supports the
trategic implementation of case-based meningitis surveillance in
urkina Faso 78 , 79 Mali, Niger 80 , Togo, and Chad, also plays an
ssential role in strengthening global meningitis surveillance. By
017, MenAfriNet had enroled 33 million people in case-based
urveillance 81 , and 92% of suspected meningitis cases had a CSF
pecimen collected, of which 26% were laboratory confirmed as
. meningitidis (56%); S. pneumoniae (40%); or H. influenzae (4%). 82 
his does, however, demonstrate that despite most cases having
SF collection, three quarters of cases still had an unidentified ae-
iology. 
Initial priorities for capacity building include improving labo-
atory capacity for and standardisation of culture and isolation of
athogens, as currently few laboratories in sub-Saharan Africa can
erform culture-based diagnostic assays. Only after this, should ef-
orts be focused on enabling DNA extraction and sequencing. In ad-
ition to resource requirements, increased laboratory capacity re-
ies on technical support from WHO CCs and other international
artners, who can provide training, quality control and molecular
haracterisation when needed. However, currently WHO CCs lack
ermanent funding and as a result several in-country laboratories
ave large and potentially valuable collections of isolates which
ave not been sequenced. At a minimum, regional sequencing ca-
acity would be beneficial since sequencing is fundamental to rep-
esentative genomic surveillance. 
hallenges to achieving representative data collections 
Ensuring that WGS repositories are up-to-date and representa-
ive is a priority, but likely to be challenging to achieve despite
lobal partners’ support. During outbreaks, rapid sharing of ge-
omic sequence data is crucial for tracking disease transmission
nd responding to developing health emergencies. In particular,
ublic health officials and clinicians need to know whether cases
re likely to be covered by available vaccines as they occur. To
chieve this, a much higher proportion of isolates would need to
e sequenced to WGS level than is currently possible. 
Current genome repositories include sequences from collec-
ions undertaken for particular public health or research initia-
ives, unsystematic collections from laboratories or hospitals, as
ell as epidemiologically representative collections. All collections
re valuable for surveillance of important disease-causing organ-
sms; however, systematic and comprehensive collection and se-
uencing from as many countries as possible is the aspiration. 
Establishing a global meningitis genome partnership / Journal of Infection 81 (2020) 510–520 517 
Fig. 4. Meningitis surveillance, 2006–2018: data on suspected meningitis cases from 18 countries south of the Sahara [Source: WHO weekly bulletin] 75 . 
Table 2 
Meningococcal isolates sent to WHO-CC’s from the laboratory-confirmed cases reported to WHO [Source: WHO weekly bulletin] 75 . 
2011 2012 2013 2014 2015 2016 
Countries Cases Isolates Cases Isolates Cases Isolates Cases Isolates Cases Isolates Cases Isolates 
Mali 29 6 94 30 6 0 12 0 23 16 44 0 
Burkina Faso 257 41 843 167 180 20 210 4 258 11 176 5 
Niger 373 17 22 0 11 0 24 0 1390 102 352 0 
Nigeria 4 0 4 0 10 7 38 5 20 9 22 14 
Chad 104 47 47 23 3 24 0 1 1 1 1 0 
Cameroon 92 0 19 4 2 0 0 0 6 0 2 0 
Benin 0 0 6 41 5 0 4 0 4 0 13 0 
Togo 2 0 9 0 4 0 1 16 36 12 307 42 
Ivory Coast 0 0 89 7 0 0 0 0 2 1 3 0 
Guinea 0 4 0 0 15 9 13 0 74 0 13 0 
CAR 0 0 4 0 0 0 0 0 0 7 56 23 
Total 861 115 1137 272 236 60 302 26 1814 159 989 84 
% isolates 13% 24% 25% 9% 9% 8% 
C
 
i  
c  
o
 
p  
t  
i  
b  
r  
P  
t  
l  
b  
c  
r
 
p  
t  
a  
i  
v  
s
V
P
 
W  
fi  
r  
v  
q  
r  
a  
s  
t  
h  
i  
1 Metadata: provide an in-depth controlled description of the sample 
that your sequence was taken from. Essentially the ‘what, where, how and 
when’ of your study from collection to sequence generation, plus contex- 
tual data such as environmental conditions or clinical observations. ( Definition 
from the European Bioinformatics Institute, Available at: https://www.ebi.ac.uk/ 
training/online/course/ebi- metagenomics- portal- submitting- metagenomics- da/ 
what- are- metadata- and- why- are- they- so- im- 0 ) hoice of clinical specimen and associated challenges 
Resource-poor settings face multiple challenges in contributing
solates to sequencing repositories. One such challenge is the diffi-
ulty in obtaining viable culture from CSF, partly due to restrictions
r reluctance in performing lumbar punctures. 
Blood samples offer an alternative solution to increase the pro-
ortion of cases for which specimens are available; however, bac-
erial load can limit successful culture recovery due to: (i) early
nfection when the organism may not be sufficiently abundant in
lood; and (ii) prior antibiotic use which clears the organism more
apidly from the bloodstream than from the CSF. In children, blood
CR may be positive for pneumococcus as a result of heavy asymp-
omatic nasopharyngeal colonisation alone. 83 , 84 Additionally, few
aboratories in low-income countries are currently able to perform
lood culture. Due to such limitations, blood sampling should be
onsidered as an additional means of confirmation, rather than a
eplacement for CSF testing. 
Another solution would be to sequence bacteria from CSF sam-
les directly. Metagenomic approaches were shown to be effec-
ive in a recent outbreak in Liberia, where no isolates were avail-
ble. 11 , 85 While contamination with non-meningitis causing organ-
sms or human DNA could reduce sensitivity and raise patient pri-
acy issues, targeted sequencing approaches or removal of human
equence data after sequencing would mitigate this risk. ision for a global meningitis genome partnership 
ublic sharing of WGS data 
A global representation of sequence-based typing including
GS is crucial; however, unique isolate identifiers should be de-
ned to allow isolates to be tracked internationally within genome
epositories. This is essential for the effective control of epidemics,
accine evaluation and development. A global overview also re-
uires genome sequence data to be open access, assembled in a
eadily interpretable and analysable manner, and associated with
ppropriate metadata. 1 Data holders are also expected to upload
hort read data to the ENA so that data are open to scrutiny. While
he data privacy issue is complex, the requirement for metadata
as to balance privacy concerns, with the objective of enabling the
nterpretation of genomic data for public health benefit. An agree-
518 Establishing a global meningitis genome partnership / Journal of Infection 81 (2020) 510–520 
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 ment on the minimum core set of associated metadata that should
be deposited with WGS data is needed. 
Clear codes of practice (COP) should be established for users of
repositories within the partnership and for data publication. The
consensus COP guidelines at their basic level, serve to secure pub-
lic access by defining the permitted uses of repositories, thus re-
assuring submitters who may have legitimate concerns about the
use of their data. 
Curation and stratification to ensure data quality 
The active curation of genome libraries is essential to ensure
data quality and enable users to interpret sequence data meaning-
fully. While automation can reduce the burden of curation, man-
ual curation will be required for a small percentage of data for the
foreseeable future. Stratification, through clear labelling of genome
libraries is essential to ensure that users understand what the li-
braries contain, how they are arranged and the origins of the iso-
lates they are studying, i.e. carriage or disease isolates, systemati-
cally collected or not. 
Overlap among different genomic platforms and databases: the 
importance of data linkage 
Existing genomic databases overlap in content and have differ-
ent but partly-overlapping functions. The interpretation of these
databases does, however, rely on the ongoing generation and main-
tenance of a unified nomenclature. For example, a fundamental
function of PubMLST is the ability to allow comparisons to be
made among isolates within a species and from multiple datasets. 
Data linkage among existing databases, facilitated by APIs, is es-
sential to achieve data harmonisation, avoid fragmentation of infor-
mation, and enable interpretation. However, while APIs have many
advantages, a caveat to their use is that sporadic download of data
may mean that users are unaware of the data source, and unknow-
ingly conduct analyses on un-representative samples, risking mis-
leading results and unwarranted assumptions. 
Aspiration for a single interface 
For a GMGP to attract submissions on a global scale, there is
an aspiration for a single interface that successfully draws from
publicly-available genomic and provenance data; however, portals
to facilitate this are needed. Combined with visualisations, such
a system would also make the valuable information gained from
WGS data more widely accessible, e.g. to public health officials,
ministries of health, global health experts, science/health journal-
ists and the broader public. Multiple levels of complexity are, how-
ever, required for different users, such that experts can continue
to undertake advanced data analysis, while non-expert groups can
engage with relevant public health information. 
Conclusions and next steps in the development of a global 
meningitis genome partnership 
While there has been a rise in the use of WGS, this has mostly
been driven by a small group of countries with adequate capac-
ity and resources to participate and benefit from performing WGS.
As a result, current WGS collections are not representative of the
global meningitis picture. The advent of the Global Roadmap to
Defeat Meningitis provides an excellent opportunity to create a
new vision for the role that sequence-based approaches, includ-
ing WGS, can play in helping to defeat meningitis by 2030, par-
ticularly through improving the global surveillance of meningitis.
A steering group is being established to coordinate the initiativend encourage high-quality data curation. Next steps in the de-
elopment of a partnership will include: (i) developing guidelines
n open-access sharing of genomic data, (ii) defining a core set
f metadata to facilitate open data sharing while protecting con-
dentiality (iii) engaging with countries not currently involved in
xisting repositories; (iv) improving countries’ capacity to culture
nd isolate pathogens; (v) consideration of the need for additional
HO CCs in different regions; (vi) improvements in visualisations
o provide data in a way people can understand while engaging
ublic health bodies, governments, epidemiologists, scientists from
ther fields, journalists, and the public; and (vii) establishment of
 pooled fund to enable capacity building and country-driven en-
agement with the partnership. 
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